EGF-Like domain of tenascin-C is proapoptotic for cultured smooth muscle cells

Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1416-21. doi: 10.1161/01.ATV.0000134299.89599.53. Epub 2004 Jun 3.

Abstract

Objective: Based on our previous observations on the expression of Tenascin-C (Tn-C) in human atherosclerotic plaques and its colocalization with macrophages, we explored whether Tn-C undergoes fragmentation and the potential pathobiological significance of this fragmentation.

Methods and results: Using cultured human smooth muscle cells (SMCs), we found that Tn-C upregulates expression of matrix metalloproteinases (MMPs). Western blot analysis revealed that Tn-C substrate is fragmented and most of the cleavage products have fibronectin-like and epidermal growth factor-like (EGF-like) domains of Tn-C. One fragment that contains an EGF-like domain was found in some human atherosclerotic plaques. Cell culture studies revealed that the recombinant EGF-like domain inhibits growth, induces apoptosis of SMCs in a dose-dependent, time-dependent, and caspase-dependent manner, and activates caspase-3 before SMC detachment. Conversely, the caspase inhibitor z-YVAD.cmk, serum, and protease inhibitors blocked cell apoptosis conferred by the EGF-like domain. In addition, these inhibitors blocked EGF-like domain-induced caspase-3 activation. In contrast to this EGF-like domain, intact Tn-C, its fibronectin-like, and its fibrinogen-like domains were inactive.

Conclusions: Together with our previous observations, our data suggest that Tn-C upregulates MMP expression that cleaves Tn-C into fragments containing the EGF-like domain. This domain has proapoptotic activity for SMCs.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Chloromethyl Ketones / pharmacology
  • Animals
  • Apoptosis / drug effects*
  • Carotid Arteries / chemistry
  • Carotid Arteries / cytology
  • Caspase 3
  • Caspase Inhibitors
  • Caspases / metabolism
  • Cell Line
  • Cricetinae
  • Cysteine Proteinase Inhibitors / pharmacology
  • Dactinomycin / pharmacology
  • Dipeptides / pharmacology
  • Enzyme Activation / drug effects
  • Enzyme Induction / drug effects
  • Epidermal Growth Factor / chemistry
  • Humans
  • Matrix Metalloproteinase Inhibitors
  • Matrix Metalloproteinases / biosynthesis
  • Mesocricetus
  • Muscle, Smooth, Vascular / cytology*
  • Myocytes, Smooth Muscle / cytology
  • Myocytes, Smooth Muscle / drug effects*
  • Oligopeptides / pharmacology
  • Peptide Fragments / chemistry
  • Peptide Fragments / pharmacology
  • Protease Inhibitors / pharmacology
  • Protein Isoforms / chemistry
  • Protein Isoforms / pharmacology
  • Protein Structure, Tertiary
  • Rats
  • Recombinant Fusion Proteins / pharmacology
  • Staurosporine / pharmacology
  • Tenascin / chemistry
  • Tenascin / pharmacology*

Substances

  • Amino Acid Chloromethyl Ketones
  • Caspase Inhibitors
  • Cysteine Proteinase Inhibitors
  • Dipeptides
  • Matrix Metalloproteinase Inhibitors
  • N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide
  • Oligopeptides
  • Peptide Fragments
  • Protease Inhibitors
  • Protein Isoforms
  • Recombinant Fusion Proteins
  • Tenascin
  • benzyloxycarbonyltyrosyl-alanyl-valyl-aspartyl chloromethyl ketone
  • Dactinomycin
  • Epidermal Growth Factor
  • chymostatin
  • CASP3 protein, human
  • Casp3 protein, rat
  • Caspase 3
  • Caspases
  • Matrix Metalloproteinases
  • Staurosporine